本文選題：降糖藥 + 用藥頻度��； 參考：《中國藥房》2015年21期

【摘要】：目的:為促進降糖藥類基本藥物在臨床的合理使用提供參考。方法:采用回顧性分析方法,對2012年5月1日-2014年4月30日我院門診降糖藥的銷售金額、用藥頻度(DDDs)、日均費用(DDC)等進行統(tǒng)計并排序、分析。結果:胰島素和口服降糖藥的銷售金額及DDDs都呈上升趨勢。口服降糖藥中銷售金額及DDDs排前3位的是阿卡波糖、二甲雙胍和格列美脲,胰島素中DDDs最高的是短效和預混重組人胰島素,均為2012年版《國家基本藥物目錄》品種;其余基本藥物格列本脲片、格列吡嗪片及中成藥DDDs均較小;長效胰島素類似物DDC明顯高于其余種類胰島素。2012年版《國家基本藥物目錄》實施后降糖藥類基本藥物銷售比例由10.48%增長到67.78%。結論:我院門診降糖藥物使用基本合理,阿卡波糖和二甲雙胍用量最大,胰島素類似物DDDs增長迅速。
[Abstract]:Objective: to provide reference for the rational use of essential drugs for hypoglycemic drugs. Methods: retrospective analysis was used to analyze the sales amount, DDDs and DDC of hypoglycemic drugs in outpatients of our hospital from May 1, 2012 to April 30, 2014. Results: the sales amount and DDDs of insulin and oral hypoglycemic drugs were on the rise. In oral hypoglycemic drugs, the top 3 places of sales amount and DDDs were acarbose, metformin and glimepiride. The highest DDDs in insulin were short-acting and premixed recombinant human insulin, all of which were the varieties of "National essential drugs catalogue" in 2012; The other essential drugs, glibenclamide tablets, glipizide tablets and Chinese patent medicine DDDs were smaller. DDC of long-acting insulin analogue was significantly higher than that of other kinds of insulin. After the implementation of National essential drugs catalogue in 2012, the sales proportion of essential drugs of hypoglycemic drugs increased from 10.48% to 67.78%. Conclusion: the use of hypoglycemic drugs in outpatient clinic of our hospital is reasonable, the dosage of acarbose and metformin is the largest, and the DDDs of insulin analogues are increasing rapidly.
【作者單位】： 首都醫(yī)科大學附屬北京友誼醫(yī)院藥劑科;
【分類號】：R95

【參考文獻】

相關期刊論文 前8條

1 莫曉虹,于瑞萍,王亞林,王東友;格列吡嗪緩釋片與格列齊特治療2型糖尿病患者的療效比較[J];貴州醫(yī)藥;2004年08期

2 王麗華;劉偉;周\，

本文編號：2087833